Gradalis
Biotechnology company developing a personalized autologous tumor-cell immunotherapy platform for treatment of solid tumors. The company conducts clinical trials (Phase 1/2), operates a cGMP manufacturing facility for patient-specific cell products, and reports translational research including biomarker analyses in oncology indications such as ovarian cancer.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Vigil (personalized autologous tumor-cell immunotherapy)
An autologous immunotherapy produced from a patient’s resected tumor tissue that is genetically modified to reduce immunosuppression and to increase immune-stimulatory signals, then irradiated and administered intradermally as multiple doses.
Vigil
Vigil is an autologous tumor cell immunotherapy that uses genetic modification to augment autologous tumor tissue, reducing immunosuppression via bifunctional shRNA targeting Furin and enhancing immune visibility with GM-CSF.
Vigil (personalized autologous tumor-cell immunotherapy)
An autologous immunotherapy produced from a patient’s resected tumor tissue that is genetically modified to reduce immunosuppression and to increase immune-stimulatory signals, then irradiated and administered intradermally as multiple doses.
Vigil
Vigil is an autologous tumor cell immunotherapy that uses genetic modification to augment autologous tumor tissue, reducing immunosuppression via bifunctional shRNA targeting Furin and enhancing immune visibility with GM-CSF.
Services
Design and execution support for oncology clinical trials including safety reporting, data management, and trial coordination.
Manufacture of genetically modified autologous tumor-cell products including processing, genetic modification, irradiation, cryopreservation and dose production.
Design and execution support for oncology clinical trials including safety reporting, data management, and trial coordination.
Manufacture of genetically modified autologous tumor-cell products including processing, genetic modification, irradiation, cryopreservation and dose production.
Expertise Areas
- Personalized cancer immunotherapy
- Cell therapy manufacturing
- Clinical trial management in oncology
- Biomarker discovery and translational research
Key Technologies
- Autologous tumor-cell immunotherapy
- Plasmid-based gene delivery
- shRNA-mediated gene knockdown
- GM-CSF transgene expression
News & Updates
Analysis from a Phase 2b randomized trial (VITAL) reporting a significant survival benefit in a molecularly defined subset of ovarian cancer patients, published and announced via press release.
Publication reporting identification of a survival-predicting biomarker in ovarian cancer patients treated with the investigational personalized immunotherapy.
Analysis from a Phase 2b randomized trial (VITAL) reporting a significant survival benefit in a molecularly defined subset of ovarian cancer patients, published and announced via press release.
Publication reporting identification of a survival-predicting biomarker in ovarian cancer patients treated with the investigational personalized immunotherapy.